Park Avenue Securities LLC Buys 2,166 Shares of Qiagen (NYSE:QGEN)

Park Avenue Securities LLC grew its stake in Qiagen (NYSE:QGEN) by 32.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,908 shares of the company’s stock after acquiring an additional 2,166 shares during the quarter. Park Avenue Securities LLC’s holdings in Qiagen were worth $397,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of QGEN. Wellington Management Group LLP increased its stake in Qiagen by 77.7% in the third quarter. Wellington Management Group LLP now owns 21,250,943 shares of the company’s stock valued at $963,386,000 after purchasing an additional 9,293,040 shares in the last quarter. Barclays PLC grew its holdings in shares of Qiagen by 170.6% in the 3rd quarter. Barclays PLC now owns 1,849,004 shares of the company’s stock valued at $84,259,000 after buying an additional 1,165,594 shares during the period. Victory Capital Management Inc. increased its position in shares of Qiagen by 62.6% in the 3rd quarter. Victory Capital Management Inc. now owns 2,574,705 shares of the company’s stock valued at $117,329,000 after buying an additional 991,325 shares in the last quarter. Point72 DIFC Ltd raised its stake in Qiagen by 10,610.4% during the 3rd quarter. Point72 DIFC Ltd now owns 649,693 shares of the company’s stock worth $29,606,000 after buying an additional 643,627 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Qiagen by 36.0% during the third quarter. JPMorgan Chase & Co. now owns 1,604,034 shares of the company’s stock worth $73,096,000 after acquiring an additional 424,937 shares in the last quarter. 70.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on QGEN shares. Jefferies Financial Group reaffirmed a “buy” rating and set a $54.00 price target (up previously from $42.00) on shares of Qiagen in a research report on Tuesday, December 10th. Morgan Stanley restated an “equal weight” rating and set a $48.00 target price (down from $50.00) on shares of Qiagen in a report on Monday, January 6th. HSBC cut shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $51.50.

Qiagen Stock Down 0.3 %

Qiagen stock opened at $45.70 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 1-year low of $39.03 and a 1-year high of $47.93. The company has a fifty day simple moving average of $44.60 and a 200 day simple moving average of $44.27. The company has a market cap of $10.43 billion, a P/E ratio of 117.18, a price-to-earnings-growth ratio of 3.49 and a beta of 0.37.

Qiagen Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.